EX-FILING FEES 14 ex107.htm CALCULATION OF FILING FEE TABLES

 

Exhibit 107

 

Calculation of Filing Fee Tables

 

S-1

(Form Type)

 

Curanex Pharmaceuticals Inc

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

   Security Type 

Security

Class

Title

 

Fee

Calculation

or Carry

Forward Rule

  

Amount

Registered(3)

  

Proposed

Maximum

Offering Price

Per Unit(1)

  

Maximum

Aggregate

Offering Price(2)

   Fee Rate  

Amount of

Registration Fee

  

Carry

Forward

Form Type

  

Carry

Forward

File Number

  

Carry

Forward

Initial

effective date

  

Filing Fee

Previously Paid

In Connection

with Unsold

Securities

to be Carried

Forward

 
Newly Registered Securities 
Fees to Be Paid  Equity  Common Stock   457(o)   4,050,000    6.00   $24,300,000   $ 0.00015310   $3720.33                              
                                                          
Fees Previously Paid                                  $-                     
Carry Forward Securities 
Carry Forward Securities                                                         
   Total Offering Amounts   $

24,300,000

   $ 0.00015310   $3720.33                     
   Total Fees Previously Paid              $-                     
   Total Fee Offsets               -                     
   Net Fee Due              $3720.33                     

 

(1) There is no current market for the securities or price at which the shares are being offered. Estimated solely for the purpose of determining the amount of registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”).
(2) Pursuant to Rule 416 under the Securities Act, there is also being registered hereby such indeterminate number of additional Ordinary Shares of the Registrant as may be issued or issuable because of stock splits, stock dividends, stock distributions, and similar transactions.
(3) Includes (a) 2,000,000 shares of common stock; (b) up to 300,000 shares of common stock that may be purchased by the underwriters pursuant to their over-allotment option to purchase additional shares; and (c) up to 1,750,000 shares of common stock to be sold by the selling stockholder.